Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

Clinical Trials

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Rapid dFLC Response Predict CHR in AL Amyloidosis

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

VelRand

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

PS-341 in Treating Patients With Advanced Cancer